Perron, Umberto
Grassi, Elena https://orcid.org/0000-0003-1066-927X
Chatzipli, Aikaterini
Viviani, Marco https://orcid.org/0000-0003-4698-8870
Karakoc, Emre
Trastulla, Lucia
Brochier, Lorenzo M. https://orcid.org/0009-0002-5306-094X
Isella, Claudio https://orcid.org/0000-0003-0679-4756
Zanella, Eugenia R.
Klett, Hagen
Molineris, Ivan https://orcid.org/0000-0003-2102-0804
Schueler, Julia https://orcid.org/0000-0003-1984-7343
Esteller, Manel https://orcid.org/0000-0003-4490-6093
Medico, Enzo https://orcid.org/0000-0002-3917-2438
Conte, Nathalie
McDermott, Ultan https://orcid.org/0000-0001-9032-4700
Trusolino, Livio https://orcid.org/0000-0002-6379-3365
Bertotti, Andrea https://orcid.org/0000-0001-8196-7608
Iorio, Francesco https://orcid.org/0000-0001-7063-8913
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (28772, 22802, 22795, 20697, 21091)
Article History
Received: 10 January 2023
Accepted: 3 October 2024
First Online: 11 November 2024
Competing interests
: FI receives funding from Open Targets, a public-private initiative involving academia and industry, and from Nerviano Medical Sciences and performs consultancy for the joint Cancer Research Horizon— AstraZeneca Functional Genomics Centre and for Mosaic T.X., L.T. has received research grants from Menarini, Merck KGaA, Merus, Pfizer, Servier and Symphogen. U.P. is a consultant for Omniscope Inc. H.K. and J.S. are employee of Charles River. U.M. is an employee and holder of company stock of AstraZeneca. All the other authors declare no competing interests.